Antiangiogenic therapy for cancer: an update.
The identification and characterization of several important regulators of angiogenesis, which led to Food and Drug Administration approval of the first antiangiogenic drugs, has opened a new era in cancer therapy. This article focuses on the clinical progress in targeting one of the major regulators of angiogenesis, vascular endothelial growth factor-A and also discusses some recent advances in the elucidation of potential cellular and molecular mechanisms underlying refractoriness or resistance to antiangiogenic therapies.
Shojaei
Farbod
F
Genentech, Inc., South San Francisco, CA 94080, USA.
Ferrara
Napoleone
N
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A